Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12778689 | 0.78 | CYP1A1 (0.32) | ALDH1A1 | |
| SCHEMBL1106198 | 0.75 | NPC1 (0.33) | SMN1; SMN2NPC1LMNATP53RAB9A | |
| SCHEMBL22140356 | 0.73 | NPC1 (0.32) | SMN1; SMN2NPC1LMNATP53RAB9A | |
| SCHEMBL22140330 | 0.73 | NPC1 (0.36) | SMN1; SMN2NPC1LMNATP53RAB9A | |
| SCHEMBL22140412 | 0.73 | NPC1 (0.32) | SMN1; SMN2NPC1LMNATP53RAB9A | |
| SCHEMBL12601238 | 0.73 | ALDH1A1 (0.39) | SMN1; SMN2NPC1LMNATP53RAB9A | |
| SCHEMBL5739987 | 0.73 | LMNA (0.48) | SMN1; SMN2NPC1LMNATP53RAB9A | |
| SCHEMBL9122746 | 0.72 | CYP1A2 (0.34) | NPC1ALDH1A1 | |
| SCHEMBL25564347 | 0.72 | — | — | |
| SCHEMBL25477385 | 0.70 | PTGS1 (0.31) | SMN1; SMN2NPC1LMNATP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230355636-A1 | COMBINATIONS OF 15-PGDH INHIBITORS WITH CORTICOSTEROIDS AND/OR TNF INHIBITORS AND USES THEREOF | UNIV CASE WESTERN RESERVE (US) | 2023-11-09 | — | — | US | disclosed |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230265100-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120190614-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230494-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7932283-B2 | Fungicide N-cyclopropyl-sulfonylamide derivatives | BAYER CROPSCIENCE AG (DE) | 2011-04-26 | — | — | US | disclosed |
| US-20100120762-A1 | Triazine derivatives as inhibitors of phosphodiesterases | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100010048-A1 | Fungicide 2-pyridyl-methylene-carboxamide derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20090137611-A1 | Fungicide N-Cyclopropyl-Sulfonylamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | SMN1; SMN2 1058/4885NPC1 2550/4885LMNA 2024/4885 |
| US-20120190614-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | SMN1; SMN2 4140/4885NPC1 241/4885LMNA 3795/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | SMN1; SMN2 1811/4885NPC1 2447/4885LMNA 2696/4885 |
| US-20230265100-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | SMN1; SMN2 1932/4885NPC1 950/4885LMNA 2114/4885 |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIPK1, RIPK2, RIPK3 | SMN1; SMN2 1682/4885NPC1 976/4885LMNA 1539/4885 |
| US-20230355636-A1 | COMBINATIONS OF 15-PGDH INHIBITORS WITH CORTICOSTEROIDS AND/OR TNF INHIBITORS AND USES THEREOF | HPGD, HPGDS, PTGS1 | SMN1; SMN2 4771/4885NPC1 2973/4885LMNA 3631/4885 |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | SMN1; SMN2 3609/4885NPC1 1750/4885LMNA 3776/4885 |
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | SMN1; SMN2 3609/4885NPC1 1750/4885LMNA 3776/4885 |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SMN1; SMN2 2352/4885NPC1 48/4885LMNA 2409/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | SMN1; SMN2 881/4885NPC1 2016/4885LMNA 1341/4885 |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | SMN1; SMN2 4324/4885NPC1 2682/4885LMNA 2546/4885 |
| US-20100010048-A1 | Fungicide 2-pyridyl-methylene-carboxamide derivatives | CYP51A1, ME2, ME3 | SMN1; SMN2 2716/4885NPC1 3978/4885LMNA 2139/4885 |
| US-20110230494-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SMN1; SMN2 2352/4885NPC1 48/4885LMNA 2409/4885 |
| US-20090137611-A1 | Fungicide N-Cyclopropyl-Sulfonylamide Derivatives | CYP51A1, ERG28, CBR3 | SMN1; SMN2 2319/4885NPC1 409/4885LMNA 3073/4885 |
| US-20100120762-A1 | Triazine derivatives as inhibitors of phosphodiesterases | PDE2A, PDE5A, PDE12 | SMN1; SMN2 3194/4885NPC1 3772/4885LMNA 4521/4885 |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, PACSIN2, MAP3K9 | SMN1; SMN2 4750/4885NPC1 3536/4885LMNA 4241/4885 |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | APLNR, AGTR1, AGTR2 | SMN1; SMN2 3107/4885NPC1 2682/4885LMNA 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.